Femoral Cartilage Thickness in Parkinson's Disease

NCT05424848 | Completed

• 1 other identifier: KAEK/2022.01.3
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Parkinson's Disease (PD) is a chronic, progressive, degenerative movement disorder characterized by motor and non-motor findings, and the incidence increases with age.There are different methods for the evaluation of articular cartilage in PD. The aim of this study is to examine the effect of cartilage thickness evaluated by US on disease stage, motor functions, balance and fall risks in individuals with Parkinson's Disease.

Conditions

Parkinson Disease; Articular Cartilage Disorder; Ultrasonography

Outcome Measures

Primary Outcomes (3)

• Ultrasonographic measurement

  Images of the intercondylar area, lateral and medial femoral condyles of the right and left knees will be taken and the measurements will be made from these areas, 3 measurements will be taken from each knee and the average of these measurements will be taken.

  Baseline

• The Hoehn and Yahr Scale

  All patients in this study were classified based on the Hoehn and Yahr scale prior to treatment. This scale is widely used for classifying PD into five stages. It permits objective evaluation of the progression of the disease, from Stage 0 (no disease symptoms) to Stage 5 (the patient is confined to a wheelchair or bed)

  Baseline

• The Movement Disorder Society Unified Parkinson's Disease rating Scale (MDS-UPDRS)

  This is an extensive scale employed for the clinical evaluation of severity of PD. It consists of four sections including non-motor findings, motor problems, motor findings, and treatment complications

  Baseline

Secondary Outcomes (2)

• Beck Depression Inventory (BDI)

  Baseline

• International Falls Efficacy Scale (FES)

  Baseline

Study Arms (2)

patient group

Inclusion Criteria 1. Having Parkinson's 2. 50-75 years old Exclusion criteria 1. Limited cooperation 2. The patient has moderate to severe dementia or mental retardation, which may cause limitations in examination, testing and treatment 3. The patient's refusal to participate in the study 4. Application of total joint prosthesis for the knee area 5. Secondary osteoarthritis

Other: Ultasonographic measurement

Control group

Healthy control group

Other: Ultasonographic measurement

Interventions

Ultasonographic measurement OTHER

Ultrasonographic measurements of the patients will be evaluated by Dr. Merve Damla Korkmaz. Patients will be positioned in a semi-dark room with the knees fully flexed. Ultrasonographic measurements will be made to evaluate the femoral cartilage thickness of both knees, with images taken from the suprapatellar axillary position. Images of the intercondylar area, lateral and medial femoral condyles of the right and left knees will be taken and the measurements will be made from these areas, 3 measurements will be taken from each knee and the average of these measurements will be taken.

Control group; patient group

Eligibility Criteria

• Age: 50 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study sample will be included with Parkinson's Disease Patient and healthy control group.

You may qualify if:

• Having Parkinson's
• years old

You may not qualify if:

• Limited cooperation
• The patient has moderate to severe dementia or mental retardation, which may cause limitations in examination, testing and treatment
• The patient's refusal to participate in the study
• Application of total joint prosthesis for the knee area
• Secondary osteoarthritis

Sponsors & Collaborators

• Kanuni Sultan Suleyman Training and Research Hospital: lead

Study Sites (1)

Kanuni Sultan Suleyman Training and Research Hospital

Istanbul, Kucukcekmece, 34303, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• merve damla korkmaz, M.D.

  Kanuni Sultan Suleyman Training and Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Study Record Dates

• First Submitted: June 13, 2022
• First Posted: June 21, 2022
• Study Start: June 15, 2022
• Primary Completion: November 25, 2022
• Study Completion: December 11, 2022
• Last Updated: December 27, 2022

Record last verified: 2022-12

Locations

TU (1)